Enter your contact info and we will call you back
Kerendia is indicated to reduce the risk of sustained
eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal
myocardial infarction, and hospitalization for heart failure in adult patients
with chronic kidney disease (CKD) associated with type 2 diabetes (T2D).
Iihyaf tgfwsbfytiqw trf68qI
erendia is a non-steroidal mineralocorticoid receptor
antagonist (MRA) indicated to reduce the risk of sustained eGFR decline, end
stage kidney disease, cardiovascular death, non-fatal myocardial infarction,
and hospitalization for heart failure in adult patients with chronic kidney
disease (CKD) associated with type 2 diabetes (T2D) erendia is a non-steroidal mineralocorticoid receptor
antagonist (MRA) indicated to reduce the risk of sustained eGFR decline, end
stage kidney disease, cardiovascular death, non-fatal myocardial infarction,
and hospitalization for heart failure in adult patients with chronic kidney
disease (CKD) associated with type 2 diabetes (T2D)
indicated to reduce the risk of sustained eGFR decline, end stage kidney
disease, cardiovascular death, non-fatal myocardial infarction, and
hospitalization for heart failure in adult patients with chronic kidney disease
(CKD) associated with type 2 diabetes (T2D)
Actual product packaging and materials may contain more and different information than what is shown on our website. We recommend that you do not rely solely on the information presented and that you always read labels, warnings, and directions before using or consuming a product.
